Synairgen says Covid treatment has shown potent antiviral activity against two Covid variants In vitro” experiments were carried out to assess the drug’s potential efficacy against the Kent and South African mutations
Synairgen PLC (LON:SNG) said lab tests of its inhaled interferon beta, which is being developed to treat people with severe effects of Covid, has shown “potent antiviral activity” against two new variants of the SARS-CoV-2.
The lab tests of SNG001 also demonstrated the “broad-spectrum antiviral activity , which bodes well for its use across a number of respiratory viruses.
The “in vitro” experiments were carried out to assess the drug’s potential efficacy against the Kent and South African Covid mutations.
Synairgen says COVID treatment has shown potent antiviral activity against two variants In vitro” experiments were carried out to assess the drug’s potential efficacy against the Kent and South African mutations
Synairgen PLC (LON:SNG) said lab tests of its inhaled interferon beta, which is being developed to treat people with severe effects of COVID, has shown “potent antiviral activity” against two new variants of the SARS-CoV-2.
The lab tests of SNG001 also demonstrated the “broad-spectrum antiviral activity , which bodes well for its use across a number of respiratory viruses.
The “in vitro” experiments were carried out to assess the drug’s potential efficacy against the Kent and South African COVID mutations.
Synairgen hails exceptional progress over 2020 towards treatment for COVID-19
The company said a Phase III trial of its SNG001 candidate was initiated last year with the results expected in the second half of 2021
Synairgen PLC’s (LON:SNG) chief executive has hailed “exceptional progress” for the group over 2020 as it continued to develop its treatment for coronavirus (COVID-19) infections.
In its results for the year to December 31, 2020, the company reported positive results and data from a number of trials of its interferon beta-1a (SNG001) treatment candidate, with the results of a Phase II trial in 101 hospitalised COVID-19 patients reported last July.